(2S,4S)-4-Fluoro-1-[(2-Methylpropan-2-Yl)Oxycarbonyl]Pyrrolidine-2-Carboxylic Acid

Within the current production landscape of long-acting dipeptidyl peptidase-4 (DPP-4) inhibitors, (2S,4S)-4-fluoro-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid functions as the exclusive chiral precursor for the 4-fluoroproline residue of omarigliptin (Merck & Co., tradename Marizev). Manufacture is governed by ICH Q7 Good Manufacturing Practice for active pharmaceutical ingredients and 21 CFR 210/211, with an associated Type II US Drug Master File commonly documenting the stereochemical integrity validated by chiral HPLC (column: Chiralpak IA, mobile phase n-hexane/ethanol/TFA 800/200/1). In the pivotal amide bond construction, the Boc-protected fluoroamino acid is charged at a molar ratio of 1.05–1.15 equivalents relative to the advanced pyrrolidine amine intermediate (2S,5R)-5-[(tert-butyloxycarbonyl)amino]-2-(2,5-difluorophenyl)-1-(pyrazolo[1,5-a]pyrimidin-3-ylcarbonyl)piperidine. Activation employs HATU (1.20 ± 0.05 eq) and N,N-diisopropylethylamine (2.50 eq) in anhydrous N,N-dimethylformamide with a moisture specification below 100 ppm KF. The reactor train comprises a 1000 L glass-lined vessel equipped with retreat-curve impeller agitation and a jacket-cooled addition funnel, maintaining internal temperature at 0–5 °C during coupling to suppress formation of the 4-epimer. Following aqueous workup, the Boc group is cleaved using 4 N HCl in 1,4-dioxane at 15–20 °C, precisely controlled to avoid pyrrolidine ring opening; the hydrochloride salt is neutralized with 2 N NaOH to liberate the penultimate amine which is extracted into isopropyl acetate and seeded at 45 °C for crystallization. The terminal active pharmaceutical ingredient obtained is omarigliptin free base, subsequently converted to the hemi-tartrate salt and compressed into oval, film-coated tablets containing 25 mg base-equivalent dose for once-weekly oral administration. Residual fluorinated process impurities (notably the (2S,4R)-isomer) are controlled below 0.15 area% by a dedicated HPLC gradient method using a phenyl-hexyl column and ion-pair reagent, ensuring pharmacological selectivity at the DPP-4 active site.

Why does the 4-fluoroproline fragment remain integral to the faldaprevir peptidomimetic backbone?

The synthesis of the hepatitis C virus (HCV) NS3/4A protease inhibitor faldaprevir (BI 201335, Boehringer Ingelheim) depends on the controlled insertion of the (2S,4S)-4-fluoro-L-proline unit, which is introduced via the Boc-protected acid in a segment condensation approach. Compliance for this intermediate stage is benchmarked against ICH Q3D elemental impurity guidelines, with palladium specifically scrutinized at <10 µg/g due to upstream hydrogenolysis steps, and residual solvent profiles aligned to ICH Q3C Class 2 limits for dichloromethane. The mixed anhydride activation protocol used in the manufacturing campaign employs isobutyl chloroformate (0.98 eq) and N-methylmorpholine (1.05 eq) in anhydrous tetrahydrofuran at −15 to −10 °C; the pre-cooled solution of the C-terminal amine partner (a nonapeptide precursor protected as tert-butyl ester) is then added in a single portion, corresponding to a stoichiometric ratio of 1.00:1.00 activated acid-to-amine. The entire operation is conducted in a 50 L Hastelloy reactor fitted with a low-temperature recirculation bath capable of maintaining setpoint tolerance within ±2 °C, which is essential because the diastereomeric purity of the resulting peptide bond can degrade by ≈0.3% per degree centigrade above −8 °C due to oxazolone-mediated epimerization. Quenching proceeds with 5% w/w aqueous citric acid monohydrate followed by extraction into ethyl acetate; the organic layer is washed sequentially with 7% w/v sodium bicarbonate and 20% w/v brine. After drying over granular magnesium sulfate in a filter-dryer, the concentrate is purified by medium-pressure liquid chromatography on silica gel 60 (63–200 µm) utilizing a heptane/ethyl acetate step gradient, and the product-containing fractions are evaporated under reduced pressure to furnish the fully protected linear intermediate. Global deprotection under acidic conditions (trifluoroacetic acid/triisopropylsilane/water 95/2.5/2.5) liberates faldaprevir sodium, which is isolated by lyophilization and intended for blending into hydroxypropyl methylcellulose capsules at a clinical dose of 120 mg once daily. LC-MS/MS trigger monitoring of the acyl glucuronide formation potential of residual aniline-like fragments is integrated into the batch release specification, a direct consequence of the compound’s acylating reactivity profile.

Boc-SPPS trans-4-fluoro-L-proline building block: microwave-assisted protocols and resin compatibility requirements

When adapted for tert-butyloxycarbonyl-based solid-phase peptide synthesis (Boc-SPPS), the intermediate must conform to a purity specification of ≥99.0% by HPLC (210 nm) and an endotoxin level below 0.05 EU/mg, as mandated for in vitro pharmacological screening libraries assembled under ISO 14644-1 Class 7 cleanroom conditions. The pre-loaded 4-methylbenzhydrylamine (MBHA) resin with a substitution capacity of 0.45 mmol/g undergoes N^α-deprotection with 50% v/v trifluoroacetic acid in dichloromethane containing 2% v/v anisole as scavenger, followed by neutralization with 10% v/v N,N-diisopropylethylamine in DMF. In the microwave-enhanced coupling cycle conducted on a CEM Liberty Blue automated synthesizer (magnetron power capped at 45 W), the Boc-(2S,4S)-4-fluoroproline is pre-dissolved in 0.4 M concentration and activated in situ with HBTU (0.49 M, 4.9 eq relative to resin loading) and diisopropylethylamine (1.0 M, 10 eq); the reaction vessel temperature is ramped to 50 °C and held for 300 s. Resin aliquots subjected to the Kaiser test after the first coupling cycle typically show a negative result (beads remain colorless), indicating a coupling efficiency exceeding 99.7%. Critical to sequence fidelity is the elimination of potassium and sodium counterions in the amino acid input, as cation adduct accumulation distorts the N-terminal Edman degradation verification; therefore, the fluorinated proline derivative is subjected to a liquid-liquid back-extraction protocol against 0.1 N HCl followed by triple washing with deionized water of resistivity 18.2 MΩ·cm before lyophilization. The penultimate step of the synthetic cycle involves simultaneous side-chain deprotection and cleavage from the resin support using liquid hydrogen fluoride containing 10% p-cresol at −2 °C for 1 h in a Kel-F apparatus. After HF removal under reduced pressure and trituration with cold diethyl ether, the crude fluoro-proline-containing peptide is separated by preparative reversed-phase HPLC (Kromasil C8 10 µm particle size, water/acetonitrile mobile phase with 0.1% TFA) to afford the final pharmaceutical-grade peptide acid, commonly destined for in vivo pharmacokinetic studies evaluating thiol protease inhibition or GPCR antagonism.

When this intermediate is deployed as a precursor for site-directed ¹⁹F spin labelling of protein ligands, stringent specifications governing paramagnetic impurity content become the dominant quality consideration. Acceptable lot release requires total iron and copper measured by inductively coupled plasma optical emission spectroscopy (ICP-OES) below 1.0 µg/g and 0.5 µg/g, respectively, and dissolved oxygen in the D₂O reconstituted stock must be purged with argon to keep the longitudinal relaxation time T₁ above 1.5 s at 470 MHz. The formulation addition ratio in a typical bioconjugation workflow calls for preceding activation of the Boc-amino acid to its N-hydroxysuccinimide (NHS) ester: the acid (1.0 eq) is treated with N,N’-dicyclohexylcarbodiimide (1.05 eq) and NHS (1.3 eq) in dry acetonitrile at 0 °C for 4 h, bypassing any aqueous quench step to avoid premature ester hydrolysis. The resulting NHS ester is isolated by filtration over a short silica plug (eluent: ethyl acetate/n-hexane 3/7), concentrated, and immediately reacted with a primary amine-bearing small-molecule warhead—most commonly a benzamidine-containing serine protease inhibitor—in a molar ratio of 1.50:1.00 (activated ester:ligand) in deuterated dimethyl sulfoxide spiked with 5% triethylamine. The reaction progress is monitored by 19F NMR observing the chemical shift perturbation of the −175.3 ppm signal, and the crude conjugate is purified by semipreparative HPLC (GraceSmart RP18 5 µm, gradient 20 to 60% acetonitrile over 25 min) to furnish the homogeneous ¹⁹F-probe. The Boc protecting group is cleaved on-resin or post-purification using a 30% trifluoroacetic acid cocktail, exposing the free pyrrolidine NH that can be re-acylated for structural diversification. Such probes serve as conformation-sensitive reporters in Förster resonance energy transfer (FRET)-paired experiments and in 19F transverse relaxation dispersion (R₂_eff) experiments designed to map millisecond-timescale protein dynamics of targets such as aldose reductase or the 20S proteasome core particle; the intermediate’s stereochemical integrity directly dictates the chemical shift anisotropy tensor orientation, making the (2S,4S) configuration non-replaceable for validation data matched to deposited BMRB entry records.

In the kilogram-scale downstream processing stream dedicated to the production of omarigliptin, the influence of post-coupling impurity purging cannot be divorced from the selection of palladium-scavenging adsorbents. After Boc-deprotection, the aqueous hydrochloride stream is passed through a packed column containing SMOPEX-234 functionalised silica (bed volume 5 L, linear velocity 1.5 cm/min) to sequester residual palladium leached from an earlier hydrogenative step, ensuring compliance with the 10 µg/g Pd limit enforced under EMA/CHMP/SWP/4446/2000. The batch record further prescribes that the crystallization cooling ramp from 45 °C to 5 °C be executed over ≥4 hours to suppress secondary nucleation, which would otherwise generate crystal fines <20 µm causing poor filtration performance on the 0.5 m² Hastelloy Nutsche filter-dryer. This phase of the process interfaces directly with a SIMATIC PCS 7 distributed control system that enforces an alarm at temperature deviation exceeding 0.8 °C/min, a protocol informed by quality-by-design experiments that correlated rapid cooling with entrapment of the des-fluoro byproduct.

A distinct risk window in faldaprevir assembly arises during the amide bond formation between the activated 4-fluoroproline and the sterically congested P2 amine: analysis of development batches run in a 20 L Büchi cyclone reactor identified that when the internal temperature transiently surpassed −4 °C for longer than 90 seconds, the level of α-proton abstraction by residual N-methylmorpholine escalated, generating up to 2.8% of the epimerized carbamate impurity. To mitigate this, a cascaded jacket control strategy with a secondary silicon oil loop was retrofitted, holding the addition phase at a setpoint of −16 °C and effectively narrowing the hot-spot excursion to below 1.2 °C throughout the 18-minute dosing period. On a different fidelity dimension, the 19F NMR probe strategy necessitates that the Boc-intermediate be vacuum-dried to ≤50 ppm residual acetonitrile because even trace CH₃CN generates a confounding sharp peak at −137 ppm in the ¹⁹F spectrum, distorting baseline correction of the target pyrrolidine resonance and complicating integration of the labelling efficiency metric derived from the 470 MHz Bruker Avance Neo spectrometer software.

In solid-phase Boc-peptide campaigns, the volume of dimethylformamide wash solvent between coupling and deprotection steps is monitored by a calibrated Coriolis flow meter set to dispense exactly 5 mL per gram of resin, a value derived to keep the residual TFA salt content below 0.05 meq/g before the subsequent coupling. Failure to meet this threshold—sometimes observed during winter production where DMF viscosity can increase by 18% at 10 °C ambient—results in incomplete neutralization and a measured coupling yield drop from 99.8% to as low as 96.4% for the sterically demanding 4-fluoro-proline residue; therefore, the process area is temperature-controlled to 22 ± 2 °C year-round. Each synthesis campaign is terminated by an independent chiral amino acid analysis on the purified peptide (acid hydrolysis with 6 N HCl at 110 °C for 22 h, derivatization with Marfey’s reagent) confirming that the (2S,4S) diastereomer composition retains an enantiomeric excess exceeding 99.9%, thereby aligned explicitly with Eur. Ph. 2.2.46 chromatographic separation techniques and safeguarding the pharmacological profile of the final GPCR-targeting peptide library.